Follow-The-Filings

Security · featured owners

TSHA Taysha Gene Therapies Inc.

Health Care COM SHS Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 1.3%
  • $28M
  • 1 new 1 add

TSHA (Taysha Gene Therapies Inc.) is held in 3 featured 13F books as of 2026 Q2. Palo Alto Investors is the largest tracked holder by portfolio weight (1.3%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.3% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors 1.3%
  2. Farallon Capital Management New 0.07%
  3. Polen Capital Management Add 0.03%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Farallon Capital Management 2026 Q2 0.07% New 0.07% 2,250,000 $15M History
Palo Alto Investors 2026 Q2 1.3% Hold 1,391,382 $9M History
Polen Capital Management 2026 Q2 0.03% Add +53.0% 489,219 $3M History

3 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 19 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
10-Q Filing Doc
8-K 1.01,2.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Jul 10, 2026 Filing Doc
4 Period Jun 1, 2026 · 4 forms Filing Doc
4 Period Apr 10, 2026 Filing Doc
4 Period Feb 4, 2026 Filing Doc
4 Period Jan 23, 2026 · 3 forms Filing Doc
4 Period Jan 12, 2026 · 3 forms Filing Doc
4 Period Nov 28, 2025 Filing Doc
4 Period Sep 10, 2025 Filing Doc
4 Period Aug 21, 2025 · 2 forms Filing Doc

Updated 19 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $15.45M $8.33M $9.77M
Net income -$111.57M -$89.3M -$109M
Net margin * -722.1% -1071.6% -1115.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $149.87M $142.13M $324.65M
Total non-current assets * $22.86M $18.23M $18.67M
Total assets $172.73M $160.36M $343.32M
Total current liabilities $36.76M $26.23M $26.55M
Total non-current liabilities * $61.04M $62.61M $69.83M
Total equity $74.94M $71.52M $246.94M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$73.02M -$81.22M -$93.09M
Cash from investing -$7.35M -$0.363M -$0.604M
Cash from financing $136.39M $76.68M $274.59M
Net change in cash $56.02M -$4.9M $180.9M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders